Merck

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced research and development capability, innovation in established brands and leveraging our U.S. manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.

Knipper Health is a leading force in the healthcare industry, serving the pharmaceutical, biotechnology, & medical device industries for more than 35 years. Our mission is to help our clients manage their brands anywhere in the product life cycle for enhanced patient well-being. We purpose-build answers specifically to address a comprehensive range of client challenges from marketing and sample management (MSM) to third-party logistics (3PL) to custom pharmacy solutions (CPS). An acknowledged leader in the sample management channel, Knipper MSM highlights Samplicity—the industry’s only fully integrated sample management platform, which features a one resource, one team, one point-of-contact approach, & a unique suite of operational services & technical advancements. KnippeRx, Custom Pharmacy Solutions (CPS) is a highly nimble, independent specialty pharmacy that serves both commercial and non-commercial needs. KnippeRx helps overcome the complex barriers to patient access by providing the shortest path from initiation of a prescription to delivery of essential therapy. Knipper 3PL provides advanced secure warehousing and distribution in life sciences. Solutions include Knipper SEAL™ (Secure Exchange of Authentic Logistics), an array of overlapping systems and processes to ensure the secure handling of your products from receiving through distribution and after delivery to your buyer. FDA/GMP and validated process controls, NAPD/VAWD and AICPS SOC accredited operations. Full support of DSCSA/DQSA, including offering full serialization system management and child-to-parent aggregation of unaggregated inventory for November 27, 2023 requirement. Cold-chain and tracking, DEA storage, flash-title to facilitate market entry, tamper evident shipment options, highly secure facilities and network, backup systems and redundancies, and more. A one-stop resource to help bring out a brand’s full potential, while elevating the patient experience to new levels of excellence.

Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible. The North America organization includes offices in Princeton, NJ; Toronto, Canada and a research facility in La Jolla, CA. Together, we work as a collaborative team to understand clinical needs and advance innovations that have a profound impact on patient lives. Our growth in North America relies on entrepreneurial team players who are willing to share their expertise and ideas in an environment that prioritizes innovation, diversity, integrity and “wa.” Each person plays a significant role in shaping the work we do and the results we deliver.